Following the recommendations of the authorities for the coronavirus pandemic, SARA Pharm has taken the necessary measures to ensure the continuity of its activity. The current projects are on-going. The laboratory is operational and the necessary precautions have been taken to allow the safe reception of samples. We do not foresee any impact on our activity to date. In the event of an evolution, we will not fail to keep you informed.

Pre-clinical Formulation Development

Excipient Screening

In direct correlation with the physchem and stability properties of the drug under study we select pharmaceutical excipients to be used into the screening process. SARA Pharm Solutions screens excipients with different chemical functionalities and diverse physchem properties with the aim of identifying a stable drug formulation.

The drug-excipients combinations are fully investigated employing different advanced methods, such as XRPD, DSC, TGA, IR, DVS, HPLC, NMR, and IC.

Although we focus on the most used solid oral dosage forms (tablets, capsules including the modified release, semi-solids), our scientists have a wealthy lab experience in topical applications and IV formulations.

Solubility Profiling & Enhancement

In our enhancing solubility studies we rationally employ a broad range of solubilizing agents such as cyclodextrin and cellulose derivatives, surfactants (eg Sodium Lauryl Sulfate, SLS), co-solvents etc.

The slurries are first equilibrated followed by the HPLC analysis of the corresponding isolated filtrates. 
The solubility improvement achieved by our scientists is an important step ensuring a successful pre-clinical formulation.